Guido Brink has over 30 years of domestic and international executive leadership experience in the diagnostics, medical device, biotechnology, and healthcare technology industries. He has proven expertise in global regulatory affairs, quality management systems, regulatory strategy, market access, and commercialization.
As a senior executive, he has held leadership positions at major healthcare organizations, including Philips, Agendia, and MDxHealth, with responsibilities spanning molecular diagnostics, oncology, medical devices, digital health, and AI-enabled healthcare technologies. His experience includes developing and executing global regulatory strategies, leading FDA submissions, establishing regulatory and quality processes, and guiding organizations through complex product development and commercialization challenges across the United States, Europe, and international markets.
His achievements include being one of the five co-founders of Agendia, where, as Regulatory Director, he was responsible for the development, submission, and successful FDA clearance of MammaPrint, a pioneering molecular diagnostic test for breast cancer prognosis.
At Philips, he held senior global regulatory leadership responsibilities across diverse medical technology and consumer healthcare businesses, supporting regulatory compliance, product development, and international market access. Throughout his career, he has advised executive leadership teams on regulatory pathways, clinical and analytical evidence requirements, quality management systems, and strategic decisions affecting product development, market entry, and commercial adoption.
As Founder and Managing Partner of GMB Advisors, established in 2018, he provides strategic and hands-on consulting services to emerging and established life sciences companies, supporting regulatory strategy, quality systems, market access, operational readiness, and commercialization.
His engagements span oncology diagnostics, cardiovascular technologies, ophthalmology, digital health, and innovative medical devices. He also supports investors and executive teams through regulatory and operational due diligence, technology assessments, risk evaluations, and strategic planning. Guido brings a practical, business-oriented approach that integrates regulatory requirements, clinical evidence, reimbursement considerations, and commercial objectives to help organizations reduce development risks, accelerate market access, and bring innovative healthcare technologies to patients.